Chiffres calculés à partir des déclarations réglementaires officielles — .
Détentioninitiés 17.79% · institutions 45.42%
En EUR · au Oct 19, 2026
Interroger la machine
Recherchez et comparez les opérations d’initiés, les sociétés et leurs statistiques en langage courant. Votre question devient une requête sur les données disponibles, pas une conversation ni un conseil en investissement.
Données de IKONISYS uniquement. Pas de recherche web. Les statistiques globales d’un initié sont exclues.
Une recherche exécutée consomme un crédit, même sans résultat. Les erreurs et les questions non prises en charge ne consomment rien.
Ikonisys S.A., a cell-based diagnostics company, develops, produces, and markets medical diagnostic products for early and accurate detection of cancer diseases in the United States and Europe. It offers Ikoniscope Robotic Microscopes, including Ikoniscope20 that provides automated slide handling, slide scanning, and real-time image capture and analysis; and Ikoniscope20max that automates the fluorescence microscopy solution. The company also provides oncoFISH bladder that allows scanning and analysis of cells from a voided urine sample; oncoFISH her2, a microscopy application for the determination of the HER2 status of tissue sections from breast tissue biopsies; oncoFISH anaplastic lymphoma kinase (ALK), a microscopy application for the FISH based detection of gene rearrangements commonly associated with non-small cell lung carcinoma; oncoFISH PTEN, a microscopy application for the FISH based detection of deletions of the PTEN gene, which is prostate tissue biopsies; circulating tumor cells for characterization of individual tumor cells and ctDNA for global tumor genotype information; Ikonisoft explorer, a FISH scanning application for analysis of cell suspension deposited on a slide that has been hybridized with desired combination of FISH probes; and IkoniWAN Gateway, a validated remote access solution for Ikoniscope digital microscopy systems. In addition, it offers liquid biopsy/CTC bladder cancer detection and breast cancer early diagnostics products; CYTOfast vial solution for any type of cellular analysis; CYTOfast kit urine, a three day cytological urine test solution; CYTOfast PLUS, a liquid-phase processor that prepares thin-layer cytological samples from liquid-phase specimen; and Ikonisys intelligent application, a software designed to automatically quantify, qualify, and present cells for review and streamlining the diagnostic process. Ikonisys S.A. was incorporated in 2021 and is headquartered in Paris, France.
Source des informations de marché · Oct 19, 2026
Chronologie sur le marché · historique complet
1 achat31 ventes— cours de clôturebarre = volume usd, échelle √cliquez sur une période pour filtrer le tableau
| Initié | Type | Valeur · USD | Signaux | Détail | |
|---|---|---|---|---|---|
| CAMBRIA CO-INVESTMENT FUND LP PARTNERSHIP | Vente | $107K | AMF |
| CAMBRIA CO-INVESTMENT FUND LP PARTNERSHIP | Vente | $33.9K | AMF |
| CAMBRIA EQUITY PARTNERS LP PARTNERSHIP | Vente | $33.9K | AMF |
| CAMBRIA CO-INVESTMENT FUND LP PARTNERSHIP | Vente | $107.6K | AMF |
| CAMBRIA CO-INVESTMENT FUND LP PARTNERSHIP | Vente | $113.1K | AMF |
| CAMBRIA EQUITY PARTNERS LP PARTNERSHIP | Vente | $76.6K | AMF |
| CAMBRIA CO-INVESTMENT FUND LP PARTNERSHIP | Vente | $91.3K | AMF |
| CAMBRIA CO-INVESTMENT FUND LP PARTNERSHIP | Vente | $93.3K | AMF |
| CAMBRIA CO-INVESTMENT FUND LP PARTNERSHIP | Vente | $87.9K | AMF |
| CAMBRIA CO-INVESTMENT FUND LP PARTNERSHIP | Vente | $3.9K | AMF |
| CAMBRIA CO-INVESTMENT FUND LP PARTNERSHIP | Attribution | $733.8K | AMF |
| CAMBRIA EQUITY PARTNERS LP PARTNERSHIP | Attribution | $44.1K | AMF |
| CAMBRIA CO-INVESTMENT FUND LP PARTNERSHIP | Vente | $30.9K | AMF |
| CAMBRIA EQUITY PARTNERS LP PARTNERSHIP | Vente | $61.6K | AMF |
| CAMBRIA EQUITY PARTNERS LP PARTNERSHIP | Vente | $67.7K | AMF |
| CAMBRIA EQUITY PARTNERS LP PARTNERSHIP | Vente | $65.4K | AMF |
| CAMBRIA EQUITY PARTNERS LP PARTNERSHIP | Vente | $75.3K | AMF |
| CAMBRIA EQUITY PARTNERS LP PARTNERSHIP | Vente | $67.9K | AMF |
| CAMBRIA EQUITY PARTNERS LP PARTNERSHIP | Attribution | $227.4K | AMF |
| CAMBRIA EQUITY PARTNERS LP PARTNERSHIP | Vente | $5.1K | AMF |
| CAMBRIA EQUITY PARTNERS LP PARTNERSHIP | Vente | $9.2K | AMF |
| CAMBRIA EQUITY PARTNERS LP PARTNERSHIP | Vente | $22.9K | AMF |
| CAMBRIA EQUITY PARTNERS LP PARTNERSHIP | Achat | $2.3K | conv 23Premier en 12 mois | AMF |
| CAMBRIA EQUITY PARTNERS LP PARTNERSHIP | Vente | $9K | AMF |
| CAMBRIA EQUITY PARTNERS LP PARTNERSHIP | Vente | $82.3K | AMF |